1
|
Davies-Bolorunduro O, Osuolale O, Saibu S, Adeleye I, Aminah N. Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects. Heliyon 2021; 7:e07710. [PMID: 34409179 PMCID: PMC8361068 DOI: 10.1016/j.heliyon.2021.e07710] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 07/25/2021] [Accepted: 07/30/2021] [Indexed: 01/01/2023] Open
Abstract
Revived analysis interests in natural products in the hope of discovering new and novel antileishmanial drug leads have been driven partially by the increasing incidence of drug resistance. However, the search for novel chemotherapeutics to combat drug resistance had previously concentrated on the terrestrial environment. As a result, the marine environment was often overlooked. For example, actinomycetes are an immensely important group of bacteria for antibiotic production, producing two-thirds of the known antibiotics. However, these bacteria have been isolated primarily from terrestrial sources. Consequently, there have been revived efforts to discover new compounds from uncharted or uncommon environments like the marine ecosystem. Isolation, purification and structure elucidation of target compounds from complex metabolic extract are major challenges in natural products chemistry. As a result, marine-derived natural products from actinomycetes that have antileishmanial bioactivity potentials have been understudied. This review highlights metagenomic and bioassay approaches which could help streamline the drug discovery process thereby greatly reducing time and cost of dereplication to identify suitable antileishmanial drug candidates.
Collapse
Affiliation(s)
- O.F. Davies-Bolorunduro
- Microbiology Department, Nigerian Institute of Medical Research, Lagos, Nigeria
- Postdoc Fellow Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Komplek Kampus C, Jl. Mulyorejo, Surabaya, 60115, Indonesia
| | - O. Osuolale
- Applied Environmental Metagenomics and Infectious Diseases Research Group (AEMIDR), Department of Biological Sciences, Elizade University, Ilara Mokin, Nigeria
| | - S. Saibu
- Department of Microbiology, University of Lagos, Akoka, Lagos, Nigeria
| | - I.A. Adeleye
- Department of Microbiology, University of Lagos, Akoka, Lagos, Nigeria
| | - N.S. Aminah
- Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Komplek Kampus C UNAIR, Jl. Mulyorejo, Surabaya, 60115, Indonesia
- Biotechnology of Tropical Medicinal Plants Research Group, Universitas Airlangga, Indonesia
| |
Collapse
|
2
|
Alcântara LM, Ferreira TCS, Gadelha FR, Miguel DC. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE 2018; 8:430-439. [PMID: 30293058 PMCID: PMC6195035 DOI: 10.1016/j.ijpddr.2018.09.006] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 09/25/2018] [Accepted: 09/26/2018] [Indexed: 01/24/2023]
Abstract
Tritryps diseases are devastating parasitic neglected infections caused by Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei subspecies. Together, these parasites affect more than 30 million people worldwide and cause high mortality and morbidity. Leishmaniasis comprises a complex group of diseases with clinical manifestation ranging from cutaneous lesions to systemic visceral damage. Antimonials, the first-choice drugs used to treat leishmaniasis, lead to high toxicity and carry significant contraindications limiting its use. Drug-resistant parasite strains are also a matter for increasing concern, especially in areas with very limited resources. The current scenario calls for novel and/or improvement of existing therapeutics as key research priorities in the field. Although several studies have shown advances in drug discovery towards leishmaniasis in recent years, key knowledge gaps in drug discovery pipelines still need to be addressed. In this review we discuss not only scientific and non-scientific bottlenecks in drug development, but also the central role of public-private partnerships for a successful campaign for novel treatment options against this devastating disease. Treatment options targeting TriTryp diseases are limited. Scientific and non-scientific bottlenecks need to be unveiled for the development of new treatments. Private and public sector partnership is key to allow advances in bench-to-bedside science.
Collapse
Affiliation(s)
- Laura M Alcântara
- Biology Institute, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil
| | - Thalita C S Ferreira
- Biology Institute, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil
| | - Fernanda R Gadelha
- Biology Institute, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil
| | - Danilo C Miguel
- Biology Institute, University of Campinas - UNICAMP, Campinas, São Paulo, Brazil.
| |
Collapse
|
3
|
Laroche M, Bérenger JM, Delaunay P, Charrel R, Pradines B, Berger F, Ranque S, Bitam I, Davoust B, Raoult D, Parola P. Medical Entomology: A Reemerging Field of Research to Better Understand Vector-Borne Infectious Diseases. Clin Infect Dis 2018; 65:S30-S38. [PMID: 28859353 DOI: 10.1093/cid/cix463] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
In the last decade, the Chikungunya and Zika virus outbreaks have turned public attention to the possibility of the expansion of vector-borne infectious diseases worldwide. Medical entomology is focused on the study of arthropods involved in human health. We review here some of the research approaches taken by the medical entomology team of the University Hospital Institute (UHI) Méditerranée Infection of Marseille, France, with the support of recent or representative studies. We propose our approaches to technical innovations in arthropod identification and the detection of microorganisms in arthropods, the use of arthropods as epidemiological or diagnostic tools, entomological investigations around clinical cases or within specific populations, and how we have developed experimental models to decipher the interactions between arthropods, microorganisms, and humans.
Collapse
Affiliation(s)
- Maureen Laroche
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille (AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille
| | - Jean-Michel Bérenger
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille (AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille
| | - Pascal Delaunay
- Service de Parasitologie-Mycologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Université de Nice-Sophia Antipolis
| | - Remi Charrel
- UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille Université, IRD 190, Inserm 1207, EHESP), AP-HM, IHU Méditerranée Infection
| | - Bruno Pradines
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille ( AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille.,Unité Parasitologie et Entomologie, Institut de Recherche Biomédicale des Armées.,Centre National de Référence du Paludisme
| | - Franck Berger
- GSBDD Marseille-Aubagne, Centre d'épidémiologie et de santé publique des armées, Marseille, France
| | - Stéphane Ranque
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille (AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille
| | - Idir Bitam
- Laboratoire Biodiversité et Environnement: Interactions Génomes, Faculté des Sciences Biologiques Université des Sciences et de la Technologie Houari Boumediene, Bab Ezzouar, Algeria
| | - Bernard Davoust
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille (AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille
| | - Didier Raoult
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille (AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille
| | - Philippe Parola
- Aix Marseille Université, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, Assistance Publique-Hôpitaux de Marseille (AP-HM), Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), IHU Méditerranée Infection, Marseille
| |
Collapse
|
4
|
Melo GD, Goyard S, Lecoeur H, Rouault E, Pescher P, Fiette L, Boissonnas A, Minoprio P, Lang T. New insights into experimental visceral leishmaniasis: Real-time in vivo imaging of Leishmania donovani virulence. PLoS Negl Trop Dis 2017; 11:e0005924. [PMID: 28945751 PMCID: PMC5629011 DOI: 10.1371/journal.pntd.0005924] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 10/05/2017] [Accepted: 09/01/2017] [Indexed: 12/26/2022] Open
Abstract
Visceral leishmaniasis is an insidious neglected disease with worldwide distribution. It is caused by parasites from the Leishmania donovani complex, which are able to be transmitted by different species of phlebotomine sand flies and to infect numerous mammal hosts. Despite the high number of people infected or at risk, and the remarkable quantity of studies focusing on this disease, a proper experimental model to efficiently decipher the infectious process of visceral leishmaniasis taking into account the nuances of parasite’s virulence and the duration of the infection is still lacking. Therefore, using golden Syrian hamsters and BALB/c mice, state-of-the-art genetic manipulation applied on a fully virulent L. donovani strain and in vivo imaging approaches, we describe herein three benefits for experimental visceral leishmaniasis: (i) the development of a double transfected bioluminescent (firefly luciferase) and fluorescent (E2-crimson) virulent strain of L. donovani (Ld1S_luci_E2-crimson), favoring a wide range of both in vivo and in vitro investigations, (ii) the establishment of a non-invasive mouse model to evaluate the infectious process during visceral leishmaniasis and the parasite’s virulence in real time, allowing longitudinal studies with the same animals, and (iii) the elaboration of a suitable method to reinstate (and verify anew) the virulence in a population of attenuated parasites, by recovering persistent parasites from chronic infected mice. Consequently, these results open up new perspectives on the study of visceral leishmaniasis, especially in the fields of therapeutics and vaccinology, since the model described herein renders now possible long-lasting follow up studies, with easy and accurate day-by-day verifications of the infection status along with a reduced number of laboratory animals. TRIAL REGISTRATION ClinicalTrials.gov 2013-0047.
Collapse
Affiliation(s)
- Guilherme D. Melo
- Institut Pasteur, Laboratoire des Processus Infectieux à Trypanosomatidés, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| | - Sophie Goyard
- Institut Pasteur, Laboratoire des Processus Infectieux à Trypanosomatidés, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| | - Hervé Lecoeur
- Institut Pasteur, Laboratoire des Processus Infectieux à Trypanosomatidés, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| | - Eline Rouault
- Institut Pasteur, Laboratoire des Processus Infectieux à Trypanosomatidés, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| | - Pascale Pescher
- Institut Pasteur, Unité de Parasitologie Moléculaire et Signalisation, Département de Parasites et Insectes Vecteurs, 25–28 rue du Dr Roux, Paris, France
| | - Laurence Fiette
- Institut Pasteur, Unité d’Histopathologie Humaine et Modèles Animaux, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| | - Alexandre Boissonnas
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, UMR 1135, CNRS, ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Boulevard de l'Hôpital, Paris, France
| | - Paola Minoprio
- Institut Pasteur, Laboratoire des Processus Infectieux à Trypanosomatidés, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| | - Thierry Lang
- Institut Pasteur, Laboratoire des Processus Infectieux à Trypanosomatidés, Département Infection et Epidémiologie, 25–28 rue du Dr Roux, Paris, France
| |
Collapse
|